What it's for (Indications)
- Ethinyloestradiol + desogestrel is primarily indicated for the prevention of pregnancy.
- This combined oral contraceptive works by providing a highly effective method of birth control when used correctly and consistently.
- Its primary role is to offer reliable contraception for women desiring to avoid pregnancy, and it does not provide protection against sexually transmitted infections (STIs).
- The selection of this specific formulation should be made after a comprehensive medical evaluation by a healthcare provider, considering the patient's individual health profile, medical history, and potential risk factors to ensure appropriate use and minimize adverse effects.
- Patients must be adequately counselled on its use.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage regimen for ethinyloestradiol + desogestrel involves taking one tablet orally at approximately the same time each day, without interruption, for 21 consecutive days. This is followed by a 7-day tablet-free interval during which a withdrawal bleed (resembling a menstrual period) usually occurs. After the 7-day break, a new pack should be started on the 8th day, irrespective of whether bleeding has ceased. For initial use, it is generally recommended to start the first tablet on the first day of the menstrual period. Adherence to the daily dosing schedule is paramount for maintaining contraceptive efficacy, and specific instructions must be followed in the event of missed pills to prevent potential contraceptive failure. |
Safety & Warnings
Common Side Effects
- Common side effects associated with ethinyloestradiol + desogestrel include nausea, vomiting, headache, breast tenderness or pain, weight changes, mood alterations (including depression), nervousness, dizziness, and breakthrough bleeding or spotting, particularly during the initial cycles of use as the body adjusts to the hormones.
- Less common but more serious adverse events can include cardiovascular complications such as venous thromboembolism (VTE), arterial thrombosis (e.
- g.
- , myocardial infarction, stroke), hypertension, and hepatic dysfunction.
- Patients should be educated to recognize and report any severe, persistent, or concerning side effects to their healthcare provider promptly for evaluation and appropriate clinical management to ensure their safety and well-being.
Serious Warnings
- Black Box Warning: Cigarette Smoking and Serious Cardiovascular Events: Cigarette smoking significantly increases the risk of serious cardiovascular events from combined oral contraceptive (COC) use. This risk escalates with advancing age, particularly in women over 35 years of age, and with the intensity of smoking. Consequently, combined oral contraceptives, including ethinyloestradiol + desogestrel, are absolutely contraindicated in women who are over 35 years of age and smoke. All women considering or using COCs should be unequivocally advised against smoking due to the substantially heightened risk of severe cardiovascular complications, including myocardial infarction, stroke, and venous thromboembolism. This critical warning underscores the imperative for thorough patient counseling regarding smoking cessation prior to initiation or continuation of these medications to mitigate potentially life-threatening adverse cardiovascular outcomes.
- Ethinyloestradiol + desogestrel carries several critical warnings.
- It is associated with an elevated risk of serious cardiovascular events, including venous and arterial thrombotic and thromboembolic events, such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
- This risk is significantly amplified in women who smoke, especially those over 35 years of age.
- Other warnings encompass an increased risk of hypertension, gallbladder disease, hepatic adenomas, and, in very rare instances, hepatocellular carcinoma.
- There is also a small, statistically significant increase in the risk of developing breast cancer and cervical cancer with long-term use.
- Discontinuation of the medication is warranted if unexplained partial or complete loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions occur, as these may signal thrombotic events.
How it Works (Mechanism of Action)
Ethinyloestradiol + desogestrel exerts its highly effective contraceptive actions primarily through three complementary mechanisms. The estrogen component (ethinyloestradiol) and the progestin component (desogestrel) synergistically suppress the hypothalamic-pituitary-ovarian axis, thereby inhibiting ovulation by preventing the release of a mature egg from the ovary. Secondly, the progestin component induces significant changes in the cervical mucus, rendering it thicker and less penetrable to sperm, which impedes their migration into the uterus. Thirdly, the hormonal combination alters the endometrial lining, making it less receptive to the implantation of a fertilized ovum. These combined pharmacological effects provide robust contraception.
Commercial Brands (Alternatives)
No other brands found for this formula.